Doctors in Vienna, Austria, recently reported a group of cases of liver cancer in 19 participants whose hepatitis C virus (HCV) was treated with direct acting antivirals (DAAs). Three of these participants had previously been diagnosed with liver cancer. Nearly all had been infected with HCV for many years and had what the doctors called "advanced liver disease."
The Austrian doctors cautioned people who read their report to bear in mind the following:
The doctors concluded that an apparently increased risk for liver cancer in some patients who have been treated with DAAs might be due to the following factor:
The Austrian doctors also found it "difficult to develop" a highly robust estimate of the risk for liver cancer in their clinic's population. However, their interim data suggest that among patients who were cured of HCV with DAAs the subsequent risk for developing liver cancer is about 5%.
They also stated that among 94 other patients in their clinic who were cured of HCV with a combination of interferon and ribavirin, 10 developed liver cancer after nearly eight years of monitoring. Thus, about 11% of these 94 interferon-treated patients developed liver cancer. This is another piece of evidence underscoring that interferon-based therapy does not provide 100% protection from the risk of developing liver cancer.
The Austrian doctors stated that their findings have several implications, including the following:
|Caution Needed About Claims of Increased Risk of Liver Cancer Recurrence With Use of DAAs|
|Barcelona: Reports of Unexpected Cases of Liver Cancer in People Undergoing Treatment With DAAs|
|Large Review From Three French Studies Finds No Link Between Use of DAAs and Recurrence of Liver Cancer|
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|Separate and Unequal Access Frames Discussion at CROI Panel on U.S. HIV Care Cascade|
|CROI 2018: Highlights and What's Next for Advocates|
|Reported PrEP 'Failure' Most Likely a Lack of Proper Testing and Adherence|
|Injection Drug Use Among People Living With HIV: A Missed Opportunity to Save Lives|
|Statin Use Might Reduce Risk of Cancer in HIV-Positive People|
|Insurers and Pharmas Must Help Fix HIV Drug Pricing System, Advocates Say|